The Asthma Control Rate Achieved by Budesonide/Formoterol in Clinical Practice in China
- Conditions
- Asthma
- Registration Number
- NCT01785901
- Lead Sponsor
- AstraZeneca
- Brief Summary
This is a multi-centre, cross-sectional study planned to be conducted in China. The study aims to observe about 1500 asthma patients who have already received budesonide/formoterol combination treatment by physicians' determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China.
- Detailed Description
The asthma control rate achieved by budesonide/formoterol in clinical practice in China.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1502
- Clinical diagnosis of asthma at least 6 months;
- Prescribed with budesonide/formoterol treatment at least 3 months before enrolled;
- Has used the same maintenance dose of budesonide/formoterol for at least 4 weeks before enrolled.
- Participation in any clinical study within 3 months;
- Have COPD history/suspicious COPD;
- ≥ 10 pack years of smoking history
- Used any other asthma maintenance medication accompanied with budesonide/formoterol within 3 months before enrolled
- With asthma exacerbation (defined as asthma symptom deterioration resulting oral/rectal/parenteral GCS medication or emergency room treatment or hospitalisation) within 4 weeks before enrolled
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of controlled and partly controlled asthma according to the definition of Global Initiative for Asthma one day
- Secondary Outcome Measures
Name Time Method The rate of completely controlled and well controlled asthma according to Asthma Control Test's score one day The average frequency of reliever use in previous week one day
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (2)
Research Site
🇨🇳Wenzhou, Zhejiang, China
Research site
🇨🇳Hangzhou, Zhejiang, China
Research Site🇨🇳Wenzhou, Zhejiang, China
